Real-world evidence on the strategy of olmesartan-based triple single-pill combination in Korean hypertensive patients: a prospective, multicenter, observational study (RESOLVE-PRO)
Abstract Background In this prospective, multicenter, non-comparative observational study, the effectiveness and safety of the triple single-pill combination (SPC) of olmesartan/amlodipine/hydrochlorothiazide (OM/AML/HCTZ) were evaluated in a real clinical practice setting in Korean patients with es...
Saved in:
| Main Authors: | Il Suk Sohn, Sang-Hyun Ihm, Gee Hee Kim, Sang Min Park, Bum-Kee Hong, Chang Hoon Lee, Sang Hyun Lee, Dae-Il Chang, Sung-Pil Joo, Sang-Chan Lee, Yong-ho Lee, Dong Woon Jeon, Kyung Tae Jung, Si Jae Rhee, Yoon-Jin Cho, Chong-Jin Kim, Investigators |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
BMC
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/71674655f6f145128963683d09f3cd73 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SIMULTANEOUS QUANTITATION OF OLMESARTAN MEDOXOMIL AND AMLODIPINE BESYLATE IN COMBINED TABLETS USING HPLC
by: QUTAB,SYED SHANAZ, et al.
Published: (2009) -
ACID- ALKALI DEGRADATION STUDY ON OLMESARTAN MEDOXOMIL AND DEVELOPMENT OF VALIDATED STABILITY-INDICATING CHROMATOGRAPHIC METHODS
by: MOUSSA,BAHIA, et al.
Published: (2010) -
Aspects of efficacy, safety and adherence to antihypertensive therapy with single pill combinations of valsartan, amlodipine and hydrochlorothiazide (Vamloset® and Co-Vamloset) in patients with 2 and 3 grade of arterial hypertension in the Russian clinical study VICTORY II
by: Irina E. Chazova, et al.
Published: (2021) -
First results of Russian multicenter prospective clinical study VICTORY II: Vamloset® and Co-Vamloset effectiveness and safety in patients with stage 2 and 3 arterial hypertension
by: I. E. Chazova, et al.
Published: (2020) -
Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation
by: Albash R, et al.
Published: (2019)